Patients would pay up to $26,500 per year for Leqembi

Few seniors with early Alzheimer’s disease will have access to the new treatment Leqembi due to its high cost and very limited coverage by Medicare. The Food and Drug Administration on Friday granted accelerated approval to Biogen and Eisai’s monoclonal antibody after the treatment appeared to modestly slow the progression of Alzheimer’s disease in clinical … Read more